Literature DB >> 33293426

Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.

Linnéa La Fleur1, Johan Botling1, Fei He2, Catarina Pelicano2, Chikai Zhou3, Chenfei He2, Giorgia Palano4, Artur Mezheyeuski1, Patrick Micke1, Jeffrey V Ravetch5, Mikael C I Karlsson6, Dhifaf Sarhan6.   

Abstract

The progression and metastatic capacity of solid tumors are strongly influenced by immune cells in the tumor microenvironment. In non-small cell lung cancer (NSCLC), accumulation of anti-inflammatory tumor-associated macrophages (TAM) is associated with worse clinical outcome and resistance to therapy. Here we investigated the immune landscape of NSCLC in the presence of protumoral TAMs expressing the macrophage receptor with collagenous structure (MARCO). MARCO-expressing TAM numbers correlated with increased occurrence of regulatory T cells and effector T cells and decreased natural killer (NK) cells in these tumors. Furthermore, transcriptomic data from the tumors uncovered a correlation between MARCO expression and the anti-inflammatory cytokine IL37. In vitro studies subsequently showed that lung cancer cells polarized macrophages to express MARCO and gain an immune-suppressive phenotype through the release of IL37. MARCO-expressing TAMs blocked cytotoxic T-cell and NK-cell activation, inhibiting their proliferation, cytokine production, and tumor killing capacity. Mechanistically, MARCO+ macrophages enhanced regulatory T (Treg) cell proliferation and IL10 production and diminished CD8 T-cell activities. Targeting MARCO or IL37 receptor (IL37R) by antibody or CRISPR knockout of IL37 in lung cancer cell lines repolarized TAMs, resulting in recovered cytolytic activity and antitumoral capacity of NK cells and T cells and downmodulated Treg cell activities. In summary, our data demonstrate a novel immune therapeutic approach targeting human TAMs immune suppression of NK- and T-cell antitumor activities. SIGNIFICANCE: This study defines tumor-derived IL37 and the macrophage scavenger receptor MARCO as potential therapeutic targets to remodel the immune-suppressive microenvironment in patients with lung cancer. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/4/956/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33293426     DOI: 10.1158/0008-5472.CAN-20-1885

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Myeloid cell-targeted therapies for solid tumours.

Authors:  Sangeeta Goswami; Swetha Anandhan; Deblina Raychaudhuri; Padmanee Sharma
Journal:  Nat Rev Immunol       Date:  2022-06-13       Impact factor: 53.106

Review 2.  Clinical relevance of tumour-associated macrophages.

Authors:  Mikael J Pittet; Olivier Michielin; Denis Migliorini
Journal:  Nat Rev Clin Oncol       Date:  2022-03-30       Impact factor: 66.675

3.  Extracellular Hsp90α stimulates a unique innate gene profile in microglial cells with simultaneous activation of Nrf2 and protection from oxidative stress.

Authors:  Yuka Okusha; Benjamin J Lang; Ayesha Murshid; Thiago J Borges; Kristina M Holton; Joanne Clark-Matott; Sachin Doshi; Tsuneya Ikezu; Stuart K Calderwood
Journal:  Cell Stress Chaperones       Date:  2022-06-10       Impact factor: 3.827

Review 4.  The pleiotropic mode and molecular mechanism of macrophages in promoting tumor progression and metastasis.

Authors:  Xingxing Zhang; Wenxiu Bai; Lisha Hu; Hualan Ha; Yuelin Du; Wei Xiong; Hongbo Wang; Panfeng Shang
Journal:  Clin Transl Oncol       Date:  2022-09-07       Impact factor: 3.340

Review 5.  Antioxidant Therapy in Cancer: Rationale and Progress.

Authors:  Maochao Luo; Li Zhou; Zhao Huang; Bowen Li; Edouard C Nice; Jia Xu; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-06-08

6.  Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes.

Authors:  Baojin Xu; Hefen Sun; Xiaoqing Song; Qiqi Liu; Wei Jin
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

7.  Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Authors:  Amaia Martinez-Usatorre; Ece Kadioglu; Gael Boivin; Chiara Cianciaruso; Alan Guichard; Bruno Torchia; Nadine Zangger; Sina Nassiri; Ioanna Keklikoglou; Martina Schmittnaegel; Carola H Ries; Etienne Meylan; Michele De Palma
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

Review 8.  Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.

Authors:  Maoyu Xiao; Jun He; Liyang Yin; Xiguan Chen; Xuyu Zu; Yingying Shen
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

9.  Exosomal circSHKBP1 participates in non-small cell lung cancer progression through PKM2-mediated glycolysis.

Authors:  Wenbiao Chen; Donge Tang; Junqi Lin; Xiaoming Huang; Shaoming Lin; Guanle Shen; Yong Dai
Journal:  Mol Ther Oncolytics       Date:  2022-02-02       Impact factor: 7.200

Review 10.  Molecular imaging of tumor-associated macrophages in cancer immunotherapy.

Authors:  Xiaoying Li; Ruike Wang; Yangnan Zhang; Shuangze Han; Yu Gan; Qi Liang; Xiaoqian Ma; Pengfei Rong; Wei Wang; Wei Li
Journal:  Ther Adv Med Oncol       Date:  2022-02-26       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.